Bulfinch – 117 Kendrick / photos by Robert Benson/Bulfinch.
Boston – Bulfinch, a Boston-based, private commercial real-estate investment firm, announced that Candel Therapeutics, a Massachusetts based biotechnology company, has signed a seven-year lease for 16,000sf of lab and office space at 117 Kendrick Street in Needham.
“We are excited to help anchor the building of the N-Squared c District biotechnology community. The location and facilities will enable us to foster a productive culture of innovation and community” stated Dr. Estuardo Aguilar-Cordova, CEO at Candel.
“We are delighted to welcome Candel as our second life sciences tenant to 117 Kendrick Street and to be able to accommodate lab users at this special asset,” said Eric Schlager, CEO of Bulfinch. “Bulfinch remains committed to growing our life science portfolio.”
Mike Wilcox, SVP at Bullfinch, added: “Our participation in the N-Squared Innovation District, as well as our current development at Cambridge Discovery Park, a 270,000sf lab and office building currently under construction and scheduled to deliver in Q1 2020, further demonstrate Bulfinch’s focus on life science and medical assets. We are dedicated to providing well-located properties and state-of-the-art spaces designed for our tenants to recruit and retain talented employees.”
117 Kendrick Street is located in Needham Crossing business park within the N-Squared Innovation District, one of Greater Boston’s leading tech hubs. The location boasts direct access to I-95/Route 128 and the 128 Business Council Shuttle Service.
Devra Bailin, Economic Development Director for the Town of Needham said “Mike Wilcox and Bulfinch have been a critical factor in the success of the Newton-Needham corridor. Their planning and development expertise along with their investment in the N-Squared District has really helped transform the area.”
